Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ex-drug executive Shkreli hid control of shares, U.S. says

Published 03/06/2016, 23:25
Updated 03/06/2016, 23:30
© Reuters. File photo of Shkreli, former CEO of Turing Pharmaceuticals LLC, appearing before a hearing in Washington
TVTX
-

By David Ingram

NEW YORK (Reuters) - U.S. prosecutors tacked on an additional criminal charge to their case against former drug executive Martin Shkreli on Friday, alleging that he tried to conceal from investors his control over unrestricted shares in Retrophin Inc (O:RTRX).

Federal prosecutors in the New York City borough of Brooklyn filed a superseding indictment with eight criminal counts against Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices. He was initially indicted in December on seven counts.

Shkreli, 33, pleaded not guilty to the earlier indictment and is awaiting a possible trial this year or next.

"The new indictment adds nothing of value to the government's case that still relies on a flawed theory as to Mr. Shkreli," his lawyer Benjamin Brafman said in a statement.

According to the new indictment, in 2012 Shkreli and Retrophin's outside counsel Evan Greebel divided 2 million of the company's unrestricted shares across seven employees and contractors in such a way as to avoid the reporting requirements of federal securities law.

Shkreli and Greebel also in effect controlled the shares by preventing some of the employees and contractors from selling them but they did not disclose that control to securities regulators, the indictment says.

Greebel, who was charged in the earlier indictment and pleaded not guilty, also faces the additional charge, bringing the number of counts against him to two. A lawyer for him declined to comment.

Last year, Shkreli sparked outrage after another company he ran, Turing Pharmaceuticals, raised the price of the drug Daraprim by more than 5,000 percent to $750 (£516.81) a pill.

© Reuters. File photo of Shkreli, former CEO of Turing Pharmaceuticals LLC, appearing before a hearing in Washington

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.